News Releases
- Mimotopes' PepSets™ to be used to identify novel proteins from the malaria parasite for next generation vaccine development
Mimotopes Awarded Major Peptide Supply Contract by the Queensland Institute of Medical Research in the Search for an Effective Malaria Vaccine
Melbourne, Australia – February 8, 2010 – Mimotopes Pty Ltd, a subsidiary of Commonwealth Biotechnologies Inc., is pleased to announce that it has been awarded a major peptide library supply contract from the Queensland Institute of Medical Research (QIMR) for screening proteins from the malaria parasite, Plasmodium falciparum. Funded by the US National Institutes of Health, the project requires the synthesis of up to 27,000 peptides derived from the Plasmodium parasite on Mimotopes’ proprietary PepSet™ peptide library platform. With the use of this technology, QIMR aims to identify those peptides that can be combined to form an effective malaria vaccine. This work builds upon Mimotopes’ recent library supply contracts for screening dengue virus and Mycobacterium tuberculosis (PRWeb December 21, 2009) and previous projects targeting Hepatitis B virus, Hepatitis C virus, human cytomegalovirus, HIV and influenza.
Read the full story at PRWeb here.
Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens
- Mimotopes PepSets to be used by the La Jolla Institute to identify regions of the dengue virus and
Mycobacterium tuberculosis that can be targeted by new vaccines
Melbourne, Australia – December 21, 2009 – Mimotopes Pty Ltd, a subsidiary of Commonwealth Biotechnologies Inc. (NASDAQ Capital Market: CBTE), is pleased to announce that it has been awarded a major supply agreement for the synthesis of peptide libraries that will be used in screening dengue virus and Mycobacterium tuberculosis. The US government-funded screening projects, to be conducted at the La Jolla Institute for Allergy & Immunology (LIAI) require the synthesis of over 30,000 peptides on Mimotopes’ proprietary PepSetTM peptide library platform. With the use of this technology, the La Jolla Institute aims to identify regions of the dengue and Tuberculosis pathogens that can be targeted by new vaccines. The synthesis of the large targeted libraries in these projects builds on Mimotopes’ recent success in producing screening libraries for Hepatitis B Virus, Hepatitis C Virus, Human cytomegalovirus, HIV, influenza and the malaria parasite.
Read the full story at PRWeb here.
Mimotopes Launches Online Peptide Superstore
- First eCommerce site dedicated to peptides and related products
- Wide range of new peptide synthesis reagents and catalogue peptides
- New pricing positions Mimotopes as the supplier of the world’s most affordable high-quality peptides
Melbourne, Australia – October 22, 2009 – Mimotopes Pty Ltd, a subsidiary of Commonwealth Biotechnologies Inc. (NASDAQ Capital Market: CBTE), is pleased to announce the launch of a new multi-currency online peptide superstore dedicated to the design, quoting, and ordering of peptides and related products. The launch of the new peptide eCommerce website comes together with an expanded range of catalogue products, including cosmetic and pharmaceutical peptides, bulk amino acids and peptide synthesis reagents. This new channel to market, together with a recent expansion in production capacity, has allowed Mimotopes to significantly reduce the pricing of its custom peptide and peptide library offerings, whilst maintaining its strong reputation for quality and customer service. The new pricing brings Mimotopes into the position of global price leader for many of its products and services.
Read the full story at PRWeb here.